Last reviewed · How we verify
GSK573719 62.5
GSK573719 62.5 is a Long-acting muscarinic antagonist (LAMA) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation.
GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | GSK573719 62.5 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
GSK573719 is an inhaled anticholinergic agent that selectively antagonizes muscarinic M3 receptors on airway smooth muscle, reducing acetylcholine-induced bronchoconstriction. This results in sustained airway relaxation and improved lung function. The drug is formulated as a once-daily maintenance therapy for chronic obstructive pulmonary disease (COPD).
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Dry mouth
- Tremor
- Headache
- Nasopharyngitis
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study (PHASE4)
- Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations (PHASE4)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators (PHASE4)
- ANTES B+ Clinical Trial (PHASE4)
- Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure (PHASE4)
- A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK573719 62.5 CI brief — competitive landscape report
- GSK573719 62.5 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK573719 62.5
What is GSK573719 62.5?
How does GSK573719 62.5 work?
What is GSK573719 62.5 used for?
Who makes GSK573719 62.5?
What drug class is GSK573719 62.5 in?
What development phase is GSK573719 62.5 in?
What are the side effects of GSK573719 62.5?
What does GSK573719 62.5 target?
Related
- Drug class: All Long-acting muscarinic antagonist (LAMA) drugs
- Target: All drugs targeting Muscarinic M3 receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Compare: GSK573719 62.5 vs similar drugs
- Pricing: GSK573719 62.5 cost, discount & access